Adamas Pharmaceuticals, Inc.

Fibrogen, Inc.

Adamas Pharmaceutical, Inc.

Seth Porter

Timothy J Fultz

Gregory T Went

Laurence R Meyerson

Timothy S Burkoth

John L Stauffer

Thomas B Neff

Frank Valone

Timothy Burkoth

The present invention relates to methods and medicaments useful for treating idiopathic pulmonary fibrosis (IPF) by administering anti-CTGF antibodies. Methods for prognosing individuals with IPF are also provided.

Methods for treating idiopathic pulmonary fibrosis

The present invention relates to methods and medicaments useful for treating idiopathic pulmonary fibrosis (IFF) by administering anti-CTGF antibodies. Methods for prognosing individuals with IPF are also provided.

Described herein are methods for treating connective tissue growth factor (CTGF)-associated cancers, including pancreatic cancer, using an anti-CTGF antibody. Increased antibody exposure was demonstrated to improve patient outcome.

Therapeutic method

Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided.

Composition and method for treating neurological disease

A method of administering amantadine is provided. The method comprises orally administering to a subject a pharmaceutical composition comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of the amantadine. A dose of the composition provides a mean change in amantadine plasma concentration as a function of time (dC/dT) that is less than 40% of the change in amantadine plasma concentration provided by a dose of the same quantity of an immediate release form of amantadine. The change in plasma concentration over time (dC/dT) is measured in a single dose human pharmacokinetic study in a defined time period of 0 to 4 hours after administration. The amantadine, or pharmaceutically acceptable salt thereof, is administered once daily at a dose of 300 to 500 mg per day.

The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject.

Method and composition for administering an NMDA receptor antagonist to a subject

The invention provides methods and compositions for treating or preventing neurological disorders.

Growing community of inventors

San Carlos, CA, United States of America

Seth Porter